U remic pruritus is a common and burdensome symptom for patients with kidney failure, affecting up to 46% of hemodialysis patients. [1] [2] [3] [4] Uremic pruritus is most commonly described as a daily or near-daily occurrence of itch that spans large bilaterally symmetrical surface areas. It does not exhibit a dermatomal pattern and there is no associated primary skin lesion. [5] [6] [7] Uremic pruritus can vary from a generalized itch to a localized itch affecting the back, face, and arms. 5 Uremic pruritus intensity is associated with multiple health-related quality-of-life outcomes, such as sleep quality, mood, and social function, 2, 7 and is independently associated with mortality. 8 Uremic pruritus has been identified as a key research priority by patients with kidney disease. 9 The pathophysiology of uremic pruritus is not fully understood and likely is multifactorial. Subclinical or overt uremic neuropathy, 10 ,11 skin or nerve inflammation in the context of kidney failure-associated chronic systemic inflammation, 2, 8, 12 or an increase in activity of m-opioid receptors due to kidney failure have all been implicated. 2, 6, 8, 13, 14 Current therapies for pruritus, such as gabapentin, 15 a modulator of excitatory neurotransmitters; cromolyn sodium, 16 a mast cell stabilizer; and capsaicin, 17 a mediator of substance P release, generally target 1 or more of these mechanisms. Although several small studies have examined a variety of interventions, the efficacy of these interventions and the optimal treatments remain poorly defined. To address this important knowledge gap, we systematically reviewed the literature and summarized the evidence for the major interventions for the treatment of uremic pruritus.
METHODS

Data Sources and Searches
We sought to summarize results of all published randomized controlled trials (RCTs) of treatments for uremic pruritus. The search strategy was designed and implemented in collaboration with a medical librarian. The following databases were searched from their inception through March 6, 2017: PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov. A combination of subject headings and MeSH terms was used as appropriate to cover the concepts of "chronic kidney disease," "hemodialysis," "peritoneal dialysis," "pruritus," and "treat." The search strategy was tailored for each database. No language restrictions were placed on the search. Retrieved citations were downloaded to EndNote, version X7.5 (Clarivate Analytics). The full search strategy is available in Item S1 (provided as online supplementary material).
Study Selection and Eligibility Criteria
Two reviewers (E.S. and B.L.) independently evaluated titles and abstracts of all citations. Any articles deemed potentially relevant by either reviewer were retrieved for full-text review. Any disagreements were resolved by consensus. If a consensus could not be reached, a third reviewer (C.R.) was consulted. Reference lists of relevant articles were manually searched for any additional relevant studies. We included prospective RCTs (parallel arm and crossover) of uremic pruritus treatments in adults (aged $18 years) with advanced chronic kidney disease (CKD; stage $ 3) or on dialysis therapy (peritoneal dialysis and hemodialysis). We included only studies using validated pruritus intensity measurement tools (visual analogue scale, verbal rating scale, and numerical rating scale). 18, 19 Appropriate translators were used for non-English articles.
Data Extraction
Data extraction was done in Microsoft Excel and verified by 2 independent reviewers (E.S. and B.L.). The information gathered from each study included the following: title, first author, journal, year of publication, location, study population, study design, period of intervention, characteristics of intervention and control, pruritus intensity measurement tool, pruritus intensity results pre-and postintervention, and adverse drug reactions (Table S1 ).
Quality Assessment and Risk of Bias
The Cochrane Collaboration's tool for assessing risk of bias was used. 20 Each selected article was assessed and given a ranking of high, low, or unclear risk in the 7 different domains (sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and "other issues") as proposed by Cochrane. Two reviewers (E.S. and B.L.) performed the risk-of-bias assessment independently. Disputes were resolved by consensus.
Statistical Analysis
The data were summarized and tabulated. A formal metaanalysis was not possible due to between-study heterogeneity in treatments, outcome measures, and design.
RESULTS
Search Results and Study Selection
The search strategy recovered 823 unique records after deduplication, and 1 extra record was identified through a hand search. Of these, 114 were identified as potentially eligible for our systematic review, and full-text articles were retrieved. Forty-four met the inclusion criteria for our review (Fig 1;  Table S2 ).
Study Characteristics
Characteristics of included studies are summarized in Table 1 . The 44 trials included a total of 2,293 patients and examined 39 different therapies. Sample sizes ranged from 10 46 to 339 patients, 36 with only 3 studies enrolling more than 100 participants. 27, 36, 56 Of the included studies, 17 originated in the Middle East; 16, East Asia; 5, Europe; 4, North America; and 2, South America. The included studies comprised a total of 14 randomized crossover trials and 30 randomized parallel-arm trials.
All studies included adults 18 years or older with the exception of 3 studies including patients 16 years and older.
48,56,60 All 44 studies included hemodialysis patients. Three studies included peritoneal dialysis patients 35, 43, 56 and 1 study included a cohort of patients with CKD stages 3 to 5. 29 Thirty-three studies measured uremic pruritus using a visual analogue scale; 11 studies, a verbal rating scale; and 1 study, a numerical rating scale. Length of treatment varied across studies, but in general was short (range, 1 week to 1 year).
Trials of Gabapentin or Pregabalin
Nine studies (total n 5 527) explored the effects of gabapentin and/or pregabalin on uremic pruritus (Table 2 ). All but one 21 used a visual analogue scale to report the results. Of these, 6 studies were parallelarm studies: 2 comparing gabapentin to placebo, 38, 41 1 comparing gabapentin to ketotifen, 21 1 comparing pregabalin to doxepin, 60 1 comparing pregabalin with both ondansetron and placebo, 56 and 1 group comparing gabapentin to usual care. 59 The remaining 3 studies were crossover studies: 2 compared gabapentin to placebo, 33, 50 and the third compared gabapentin to pregabalin in a population with established neuropathy and/or neuropathic pain. 47 Overall, when gabapentin or pregabalin was compared to placebo, there was a statistically significant benefit in favor of the active treatment. 33, 38, 41, 50, 56 In 2 studies in which gabapentin was compared to an active comparator (ketotifen or pregabalin), no significant difference was seen in treatment benefit. 21, 47 When pregabalin was compared to doxepin, there was a significant benefit in favor of pregabalin. 60 None of these trials examined the long-term effects of treatment, with the longest treatment duration being 12 weeks. 56 The most common adverse effects for gabapentin, pregabalin, and ketotifen included drowsiness, dizziness, and somnolence (Table 2) .
Trials of Mast Cell Stabilizers
Five studies (total n 5 237) examined medications thought to prevent the degranulation of mast cells (Table 2 ). All studies were parallel arm with the exception of 1 crossover trial. 40 Each trial used a visual analogue scale to measure pruritus intensity.
One crossover study compared the histamine H 1 antagonist hydroxyzine to Avena sativa (oat) extract and diluted vinegar. 40 There was no statistically significant difference in the decrease in uremic pruritus intensity between these treatments. Cromolyn sodium was compared against placebo in 2 studies. 30 ,51 A significant reduction in pruritus intensity was observed in the cromolyn group. Nicotinamide, a potent stabilizer of mast cells and leukocytes, was studied in 1 parallel-arm trial. 42 Nicotinamide was not found to be more effective than placebo. Oral zinc sulfate was examined in 1 trial and was demonstrated to be more effective than placebo in relieving pruritus. 39 No trial looked at the long-term effects of treatment, with the longest trial being 8 weeks in duration. 39, 51 The only noted adverse effects were for cromolyn sodium; they included a burning sensation and flatulence. 
Trials of Phototherapy
Four studies (total n 5 112) included in our review examined the effects of phototherapy on uremic pruritus (Table 2 ). All 4 were parallel-arm studies. A visual analogue scale and verbal rating scale were used in 2 studies each. Three trials compared the effects of UV-B therapy to UV-A therapy 31, 32, 35 ; 1 specifically used narrow-band UV-B. 35 All studies varied the dose of UV therapy based on the patient's skin characteristics. The 2 studies using broadband UV-B indicated a significant benefit in favor of UV-B therapy over UV-A. 31, 32 In contrast, the study comparing narrow-band UV-B to UV-A showed no statistically significant benefit of narrow-band UV-B therapy compared to UV-A therapy. 35 Sunburn and tanning were noted side effects of the UV-B therapy. Far-infrared ray thermal therapy was compared to a control in 1 study. No statistically significant effect of far-infrared ray was detected compared to the control group. 34 
Trials of Hemodialysis Prescription Modification
Five studies (total n 5 312) compared the effects of hemodialysis prescription modification on uremic pruritus. 24, 27, 57, 61, 64 All measured pruritus using a visual analogue scale, 4 were parallel-arm studies, and 1 was a crossover study. Two studies examined the effects of high-flux hemodialysis. 57, 61 One compared the effects of using high-flux hemodialysis against hemodialysis filtration, 61 whereas the other compared it to a low-flux hemodialysis control. 57 Both determined that high-flux hemodialysis was significantly better in improving pruritus intensity. One study compared the efficacy of hemodiafiltration with hemoperfusion against hemodialysis with hemoperfusion. They determined that hemodiafiltration with hemoperfusion was more effective in relieving uremic pruritus. 64 One study compared the effects of high-permeability hemodialysis (ultrafiltrate coefficient, 40 mL/h/mm Hg) to conventional hemodialysis (ultrafiltrate coefficient, 5.5 mL/h/mm Hg). This study found a statistically significant improvement in uremic pruritus with high-permeability versus conventional hemodialysis. 27 One study compared the efficacy of magnesium-free dialysate to conventional dialysate and showed no difference between groups.
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Trials of Other Systemic Medications
Montelukast Montelukast, a leukotriene receptor antagonist, was compared to placebo in 1 trial with 80 hemodialysis patients. This parallel-arm study determined using a visual analogue scale that montelukast significantly improved uremic pruritus over placebo. 62 No adverse drug reactions were recorded.
Nalfurafine Hydrochloride
The efficacy of nalfurafine hydrochloride (HCl), a novel selective k-opioid receptor agonist, was examined in 2 studies (n 5 339 and n 5 79). 36, 52 Both used a visual analogue scale to determine the change in pruritus intensity. One parallel-arm study compared the efficacy of oral nalfurafine HCl, 5 or 2.5 mg, to placebo. It revealed a statistically significant benefit of both nalfurafine HCl 5 and 2.5 mg over placebo. 36 The second study, using nalfurafine HCl 5 mg given intravenously, included both a parallel-arm and a secondary crossover trial. The result of the primary parallel-arm study showed no significant benefit in favor of the nalfurafine infusion. 52 Common adverse effects of nalfurafine HCl included headache, nausea, and insomnia (Table 2 ).
Ondansetron
Two randomized crossover trials (n 5 19 and n 5 24) compared the effects of oral ondansetron to placebo. Both determined on a visual analogue scale that there was no statistically significant effect of ondansetron over placebo in relieving pruritus. 22, 37 No side effects were reported for either study.
Naltrexone
The effect of naltrexone was examined in 2 randomized crossover studies with conflicting results. Both studies used oral naltrexone, 50 mg, once daily. However, 1 study examined the effects of the medication over 4 weeks with 23 participants, 43 whereas the other was over 1 week with 15 participants. 44 The study with the longer duration and more participants determined that the effect of naltrexone was not statistically significant when compared to placebo. 43 The study with shorter duration and fewer participants concluded that there was a significant effect of naltrexone compared to placebo. 44 
Primrose Oil
One study (n 5 16) compared the effects of oral evening primrose oil enriched with gamma-linoleic acid (GLA) to oral linoleic acid on uremic pruritus. This study used a 5-point verbal rating scale to determine that pruritus intensity was not significantly different between the 2 treatments.
54
Cholestyramine Another study (n 5 10) compared the effects of cholestyramine with those of a placebo in a parallel-arm design. Eighty percent of patients gained either full or considerable relief of pruritus with cholestyramine, whereas only 20% of patients responded in a similar fashion to the placebo. It was not noted if the difference between the 2 treatments reached statistical significance.
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Uremic Pruritus Treatment 
Thalidomide
One study (n 5 29) observed the effects of thalidomide compared to placebo in a randomized crossover trial. Using a 4-point verbal rating scale, this study concluded that a statistically significant benefit was reached in favor of thalidomide. 45 
Trials of Other Topical Treatments
Eight articles studied the effects of other topical treatments (Table 2) .
GLA-Enriched Cream GLA-enriched cream was compared to placebo in 1 crossover study (n 5 17) and demonstrated a statistically significantly improvement in pruritus severity for this treatment. 26 
Capsaicin Cream
Two crossover studies (n 5 22 and n 5 19) compared the effect of capsaicin 0.025% cream applied to 1 affected site versus placebo. 28 ,49 Both Absolute effect, absence of pruritus or some effect; reduction of pruritus and daily activity and sleep no longer impaired. used a 4-point verbal rating scale and found a significant benefit in favor of capsaicin cream. The most common adverse effects included local burning, stinging, and redness.
Dead Sea Mineral Lotion
One parallel-arm study (n 5 78) compared the effects of Dead Sea mineral lotion with 2 different comparators. Using a 5-point verbal rating scale, the R a n d o m S e q u e n c e G e n e ra ti o n A ll o c a ti o n C o n c e a lm e n t B li n d in g o f P a rt ic ip a n ts a n investigators concluded that there was no significant effect on pruritus intensity among the 3 treatments.
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Pramoxine Lotion One parallel-arm study (n 5 28) of 1% pramoxine HCl determined that there was a significant benefit of the pramoxine lotion over the control lotion. 55 Tacrolimus Ointment Tacrolimus 0.1% ointment was compared against a control in 1 parallel-arm study (n 5 22) . This study demonstrated that there was no significant benefit of tacrolimus ointment over control. 29 A warm sensation was noted as a common side effect.
Chinese Herbal Cream
One study evaluated the efficacy of a Chinese herbbased cream to a lotion with no active ingredients in a parallel-arm study (n 5 80). With the use of a 5-point verbal rating scale, it was determined that the herbbased cream was significantly more effective in decreasing pruritus intensity than the control. 58 Sarna and Eurax Lotions Last, there was 1 crossover trial (n 5 31) that compared the effects of Sarna lotion (0.5% of each camphor, menthol, and phenol) to Eurax lotion (10% crotamiton). There was no significant difference in benefit between the 2 lotions. 48 
Trials of Alternative Treatments
Three trials of alternative treatments met criteria for this review. 25, 53, 63 Two studies looked at the effect of acupressure on uremic pruritus. 53, 63 One study (n 5 75) compared the effects of acupressure at the LI to L11 spot to transcutaneous electrical acupoint stimulation and a control. This study determined that both transcutaneous electrical acupoint stimulation and acupressure were more effective than a control at relieving uremic pruritus based on visual analogue scoring. One study (n 5 71) observed the effects of auricular acupressure with a vaccaria seed compared to a control (tape placed on the same 6 auricular acupressure points). 53 This study determined on a visual analogue scale that auricular acupressure was more effective than a control in decreasing pruritus intensity. In another study (n 5 28), a homeopathic verum medication was studied against a placebo. By the end of the study, the verum medication did not reach a statistically significant benefit for pruritus when compared to the placebo. 25 
Quality of Reporting and Risk of Bias of Included Studies
All potentially relevant sources of bias, including funding sources, were evaluated for each individual study (Tables S3 and S4 ). There was a high or unclear risk of bias in most of the included studies, as determined using the Cochrane Collaboration's riskof-bias tool. We summarized individual (Fig 2) and aggregate (Fig 3) risk of bias for the included studies. Overall, the methods and outcomes were poorly described in most studies. Risks of selection biases were unclear because methods of random sequence generation and allocation concealment were poorly described in the majority of studies. Reporting of outcomes was also often incomplete, with potential for bias. In particular, rates of attrition and reasons for exclusion were not properly described in many studies. Two potentially important sources of bias relate to blinding of participants and personnel and blinding of outcome assessment. Because pruritus is a subjective measurement, studies in which the patients have not been blinded to their intervention could bias how they perceive and score their pruritus intensity. Two studies were given a mark of high in the category of "other bias." One study had a major discrepancy in reported results between the written discussion and the tables. 42 We tried unsuccessfully to contact the author to resolve these discrepancies. Another study mentioned changes to the initial treatment regimen but never specified initial and subsequent dosing.
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DISCUSSION
The main finding of our comprehensive systematic review of treatments for uremic pruritus is that with the exception of the evidence for gabapentin, there remains considerable uncertainty about effective treatments for this important and burdensome symptom in patients with kidney failure. Despite a large trial literature examining multiple different interventions, the combination of flawed methodology, high risk of bias, small sample size, and study heterogeneity prevent the generation of robust treatment recommendations. High-quality studies are urgently needed to bridge this major gap between research output and identified patient priorities. 9 Five previous systematic reviews have attempted to evaluate individual treatments for uremic pruritus. [65] [66] [67] [68] [69] These reviews have addressed the efficacy of gabapentin, 65 acupuncture, 66 ondansetron, 67 capsaicin, 68 and omega-3 fatty acids. 69 The review of gabapentin in hemodialysis patients by Lau et al 65 included 7 studies with a total of 179 patients: RCTs, quasi-RCTs, observational studies, open-label studies, and retrospective studies were included. This review supported a trial of gabapentin for hemodialysis patients with refractory uremic pruritus. Kim et al 66 reviewed the literature regarding the effect of acupuncture on uremic pruritus. Six studies were included in the review, with various study designs including RCTs, uncontrolled observational studies, and a controlled clinical trial. The authors concluded that there was a lack of evidence to support the use of acupuncture for uremic pruritus. Panahi et al 69 reviewed the literature on omega-3 fatty acids on uremic pruritus. They included all prospective English-language studies. The review supported omega-3 intake in patients with CKD with uremic pruritus. Gooding et al 68 and To et al 67 examined the literature with regard to capsaicin and ondansetron, respectively. Both reviews included varying causes of pruritus and were not exclusive to uremic pruritus.
Our analysis distinguishes itself from these previous studies in several important ways. First, we examined a broader range of treatments in order to better describe the full spectrum of RCT evidence on the treatment of uremic pruritus. Second, we included only RCTs in our review. Such trials are the optimal study design for estimating treatment effects, in large part because random allocation minimizes imbalances in both known and unknown confounders between groups. This property is especially relevant when examining effects of therapy for a subjective symptom such as pruritus, in which the pathophysiology is not completely understood. In such cases, observational analyses often lead to biased estimates of treatment effect as a result of significant residual confounding by unknown factors. In addition, we only included studies that used a well-validated tool for assessment of pruritus because otherwise it would be difficult to compare and generalize results across studies.
Uremic pruritus remains a clinical priority for patients with CKD. 9 Despite this, our review highlights a clear lack of large simple randomized trials and underscores a critical knowledge gap. The current body of literature, dominated by small trials with high risk of bias, is not sufficient to establish optimal therapies. Large simple parallel-arm trials addressing some of the more promising therapies studied, such as gabapentin and capsaicin, are urgently needed. To ensure generalizability and relevance to patients and care providers, such trials need to be broadly inclusive of patients with kidney disease and pruritus, should measure itch using validated and reproducible tools, and should incorporate validated metrics of important patient-centered outcomes such as sleep and quality of life. Validation of novel multidimensional tools to measure pruritus could be incorporated into such studies. 19, 70 Finally, translational substudies should be embedded within these trials to address questions about the underlying mechanism and help refine targets for therapy.
In the absence of these trials, the main clinical implication of our review is that because optimal therapy is uncertain, patients and physicians are justified in trying different therapy options to identify the most effective treatment for an individual patient. A formal N-of-1 trial as originally suggested by Sackett may be appropriate in some cases. 71 Our review has several strengths. We followed all PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines for the conduct and reporting of systematic reviews. To minimize selection bias, we electronically searched multiple databases using prespecified PICO (population, intervention, comparison, outcome) criteria and supplemented this search with a manual search of references from included studies. We also included studies examining a broad range of treatments for uremic pruritus spanning several known potential mechanisms of pruritus in kidney disease. A limitation of our review was inclusion of only published literature. Although our search yielded studies with negative results, we cannot exclude a publication bias toward studies with positive findings. Also, the large degree of heterogeneity between studies did not permit combining of study results in a formal meta-analysis.
In conclusion, although uremic pruritus is an important and often debilitating symptom for patients with kidney failure, overall, the current evidence base for its treatment is weak and limited by small studies with a high risk of bias. The largest body of evidence was found for the effectiveness of gabapentin. Large, methodologically rigorous, parallel-arm RCTs are urgently needed. Manitoba. Funders of this study had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit this report for publication.
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